Malaria: Difference between revisions
From WikiDemocracy
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 183: | Line 183: | ||
[https://www.sciencedirect.com/science/article/abs/pii/S0140673615607218 by RTS,S Clinical Trials Partnership ScienceDirect] | [https://www.sciencedirect.com/science/article/abs/pii/S0140673615607218 by RTS,S Clinical Trials Partnership ScienceDirect] | ||
The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up have been published previously. Herein, we report the final results from the same trial, including the efficacy of a booster dose. | The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up have been published previously. Herein, we report the final results from the same trial, including the efficacy of a booster dose. | ||
=====A Research Agenda for Malaria Eradication: Vaccines===== | |||
[https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000398 by The malERA Consultative Group on Vaccines 25/1/11 PLOS Medicine] | |||
Vaccines could be a crucial component of efforts to eradicate malaria. Current attempts to develop malaria vaccines are primarily focused on Plasmodium falciparum and are directed towards reducing morbidity and mortality. Continued support for these efforts is essential, but if malaria vaccines are to be used as part of a repertoire of tools for elimination or eradication of malaria, they will need to have an impact on malaria transmission. | |||
